Receipt of opioid agonist treatment in the Veterans Health Administration: Facility and patient factors

Drug and Alcohol Dependence

Volumn 122, Issue 3, 2012, Pages 241-246

  Oliva, Elizabeth M ^a   Harris, Alex H S ^a   Trafton, Jodie A ^a   Gordon, Adam J ^b  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Buprenorphine; Methadone; Opioid related disorders; United States Department of Veterans Affairs

Indexed keywords

BUPRENORPHINE; METHADONE; OPIATE AGONIST;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG DEPENDENCE; EVIDENCE BASED PRACTICE; FEMALE; GOVERNMENT; HEALTH CARE FACILITY; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HEALTH PROGRAM; HEALTH SERVICE; HUMAN; MALE; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; PATIENT; PREDICTOR VARIABLE; PRIORITY JOURNAL; VETERANS HEALTH;

ADULT; AGE FACTORS; BUPRENORPHINE; FEMALE; HOSPITALS, VETERANS; HUMANS; MALE; METHADONE; MIDDLE AGED; OPIOID-RELATED DISORDERS; SEX FACTORS; TREATMENT OUTCOME; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS; VETERANS HEALTH;

EID: 84859627296     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2011.10.004     Document Type: Article

References (23)

1. Alford D.P., LaBelle C.T., Richardson J.M., O'Connell J.J., Hohl C.A., Cheng D.M., Samet J.H. Treating homeless opioid dependent patients with buprenorphine in an office-based setting. J. Gen. Intern. Med. 2007, 22:171-176.
2. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 1995, American Psychiatric Association, Washington. fourth ed.
3. American Psychiatric Association, 2010. APA Announces Draft Diagnostic Criteria for DSM-5: New Proposed Changes Posted for Leading Manual of Mental Disorders. American Psychiatric Association, Arlington, VA. Retrieved March 22, 2011, from http://www.dsm5.org/Newsroom/Documents/Diag%2520%2520Criteria%2520General%25%2020FINAL%25202.05.pdf.
4. Barnett P.G. Comparison of costs and utilization among buprenorphine and methadone patients. Addiction 2009, 104:982-992.
5. Bell J., Trinh L., Butler B., Randall D., Rubin G. Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment. Addiction 2009, 104:1193-1200.
6. Cornish R., Macleod J., Strang J., Vickerman P., Hickman M. Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database. BMJ 2010, 341:c5475.
7. Department of Veterans Affairs, 2009. Veterans Health Administration. Uniform Mental Health Services in VA Medical Centers and Clinics. (accessed on 23.03.09). http://www1.va.gov/vhapublications/ViewPublication.asp%3Fpub_ID=1762.
8. Fiellin D.A., Moore B.A., Sullivan L.E., Becker W.C., Pantalon M.V., Chawarski M.C., Barry D.T., O'Connor P.G., Schottenfeld R.S. Long-term treatment with buprenorphine/naloxone in primary care: results at 2-5 years. Am. J. Addict. 2008, 17:116-120.
9. Fiellin D.A., Pantalon M.V., Chawarski M.C., Moore B.A., Sullivan L.E., O'Connor P.G., Schottenfeld R.S. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N. Engl. J. Med. 2006, 355:365-374.
10. Fudala P.J., Bridge T.P., Herbert S., Williford W.O., Chiang C.N., Jones K., Collins J., Raisch D., Casadonte P., Goldsmith R.J., Ling W., Malkerneker U., McNicholas L., Renner J., Stine S., Tusel D. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N. Engl. J. Med. 2003, 349:949-958.
11. Goodman, F., Gordon, A., Kivlahan, D., Dalack, G., McNicholas, L., Oslin, D., Saxon, A., Suchinsky, R., for the VHA Pharmacy Benefits Management Strategic Healthcare Group and the Medical Advisory Panel, 2007. Criteria for use of buprenophine/naloxone and Buprenorphine sublingual tablets. (accessed on 04.11.11). http://www.pbm.va.gov/Clinical%20Guidance/Criteria%20For%20Use/Buprenorphine,%20Criteria%20for%20Formulary%20Use.pdf.
12. Gordon A.J., Kavanagh G., Krumm M., Ramgopol R., Paidisetty S., Aghevli M., Goodman F., Trafton J., Liberto J. Facilitators and barriers in implementing buprenorphine in the Veterans Health Administration. Psychol. Addict. Behav. 2011, 25:215-224.
13. Gordon A.J., Trafton J.A., Saxon A.J., Gifford A.L., Goodman F., Calabrese V.S., McNicholas L., Liberto J. Implementation of buprenorphine in the Veterans Health Administration: results of the first 3 years. Drug Alcohol Depend. 2007, 90:292-296.
14. Harris A.H., Gospodarevskaya E., Ritter A.J. A randomised trial of the cost effectiveness of buprenorphine as an alternative to methadone maintenance treatment for heroin dependence in a primary care setting. Pharmacoeconomics 2005, 23:77-91.
15. Jones E.S., Moore B.A., Sindelar J.L., O'Connor P.G., Schottenfeld R.S., Fiellin D.A. Cost analysis of clinic and office-based treatment of opioid dependence: results with methadone and buprenorphine in clinically stable patients. Drug Alcohol Depend. 2009, 99:132-140.
16. Lewis D.C. Access to narcotic addiction treatment and medical care: prospects for the expansion of methadone maintenance treatment. J. Addict. Dis. 1999, 18:5-21.
17. Mattick R.P., Kimber J., Breen C., Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst. Rev. 2008, CD002207.
18. Mattick R.P., Breen C., Kimber J., Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst. Rev. 2009, CD002209.
19. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction Effective medical treatment of opiate addiction. JAMA 1998, 280:1936-1943.
20. Oliva E.M., Maisel N.C., Gordon A.J., Harris A.H.S. Barriers to use of pharmacotherapy for addiction disorders and how to overcome them. Curr. Psychiatry Reports 2011, 13(5):374-383.
21. Parran T.V., Adelman C.A., Merkin B., Pagano M.E., Defranco R., Ionescu R.A., Mace A.G. Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy. Drug Alcohol Depend. 2010, 106:56-60.
22. Stein M.D., Cioe P., Friedmann P.D. Buprenorphine retention in primary care. J. Gen. Intern. Med. 2005, 20:1038-1041.
23. Sullivan L.E., Moore B.A., Chawarski M.C., Pantalon M.V., Barry D., O'Connor P.G., Schottenfeld R.S., Fiellin D.A. Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors. J. Subst. Abuse Treat. 2008, 35:87-92.